Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

Boan Biotech Secures FDA Orphan Drug Designations for Pancreatic Cancer Treatments

Fineline Cube Dec 29, 2023

China-based Boan Biotech (HKG: 6955) has announced that its novel antibody BA1105 and antibody-drug conjugate...

Company Deals

Eli Lilly Teams Up with Fauna Bio to Uncover New Anti-Obesity Drug Targets

Fineline Cube Dec 29, 2023

Eli Lilly (NYSE: LLY) has entered a collaboration agreement with fellow U.S. firm Fauna Bio...

Company Drug

Gilead’s Kite Receives FDA Nod to Add Overall Survival Data to Yescarta for Large B-Cell Lymphoma

Fineline Cube Dec 29, 2023

Gilead Sciences Inc. (NASDAQ: GILD) subsidiary Kite has received approval from the U.S. Food and...

Company Drug

FDA Prioritizes Roche’s Xolair for Food Allergy Indication Extension Ahead of Q1 Decision

Fineline Cube Dec 29, 2023

The U.S. Food and Drug Administration (FDA) has prioritized Roche’s (SWX: ROG) indication extension filing...

Company Drug

Lepu Biotechnology Completes Enrollment for Phase IIb Trial of MRG003 in Nasopharyngeal Carcinoma

Fineline Cube Dec 29, 2023

Lepu Biotechnology Co., Ltd (HKG: 2157), based in China, has announced the completion of subject...

Company Medical Device

Sino Medical Secures Approvals for Key Coronary Devices in Taiwan, India, and Uzbekistan

Fineline Cube Dec 29, 2023

Sino Medical Sciences Technology Inc. (SHA: 688108), a China-based medical device company, has announced that...

Company Drug

Shanghai Henlius Secures Indonesian Approval for HanSiZhuang in Small-Cell Lung Cancer

Fineline Cube Dec 29, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696) has received market approval from the Indonesian Food and...

Company Deals

IVD Medical Ends Strategic Partnership with Japan’s Sysmex in Coagulation Products

Fineline Cube Dec 29, 2023

IVD Medical Holding Ltd (HKG: 1931), a China-based in vitro diagnostic (IVD) specialist, has announced...

Company Drug

Clover Biopharma’s SCB-219M Shows Promising Phase I Results for Chemotherapy-Induced Thrombocytopenia

Fineline Cube Dec 29, 2023

Clover Biopharmaceuticals Ltd (HKG: 2197), based in China, has announced promising preliminary results from its...

Company Deals

Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio

Fineline Cube Dec 28, 2023

Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT)...

Company Drug

Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment

Fineline Cube Dec 28, 2023

Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate...

Company Deals

CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies

Fineline Cube Dec 28, 2023

China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm...

Company Medical Device

Cryofocus Medtech Secures NMPA Approval for Cryotherapy Equipmen

Fineline Cube Dec 28, 2023

Shanghai-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) has announced that it has received marketing...

Company Drug

Simcere Secures Approval for Local Manufacturing of Cosela, Boosting Patient Access

Fineline Cube Dec 28, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has received supplementary filing approval for its drug Cosela...

Company

Chengda Pharmaceuticals Halts Shanghai Research Project Amid Market Challenges

Fineline Cube Dec 28, 2023

Chengda Pharmaceuticals Co. Ltd. (SHE: 301201), based in China, has announced the termination of its...

Company Deals

TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical

Fineline Cube Dec 28, 2023

Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly...

Company Medical Device

NMPA Approves Pulnovo Medical’s Novel Catheter for Treating Pulmonary Arterial Hypertension

Fineline Cube Dec 28, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for Pulnovo Medical’s disposable circular...

Company Deals

Innovent Biologics Partners with Xuanzhu Biopharma for Clinical Trial of Sintilimab and KM-501 in Advanced Tumors

Fineline Cube Dec 28, 2023

Innovent Biologics, Inc. (HKG: 1801), based in China, has entered into a clinical trial collaboration...

Company Drug

Sanofi Gains NMPA Approval for Innovative Rosuvastatin and Ezetimibe Combination Therapy

Fineline Cube Dec 28, 2023

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced that it has received market approval...

Company Deals

Janssen Acquires Rights to Gene Therapy Botaretigene Sparoparvovec from MeiraGTx for XLRP Treatment

Fineline Cube Dec 28, 2023

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), announced last week its...

Posts pagination

1 … 423 424 425 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.